PE20252763A1 - Medicamento de combinacion fija para el control y manejo del dolor neuropatico - Google Patents

Medicamento de combinacion fija para el control y manejo del dolor neuropatico

Info

Publication number
PE20252763A1
PE20252763A1 PE2023002012A PE2023002012A PE20252763A1 PE 20252763 A1 PE20252763 A1 PE 20252763A1 PE 2023002012 A PE2023002012 A PE 2023002012A PE 2023002012 A PE2023002012 A PE 2023002012A PE 20252763 A1 PE20252763 A1 PE 20252763A1
Authority
PE
Peru
Prior art keywords
management
pharmaceutically acceptable
control
neuropathic pain
fixed combination
Prior art date
Application number
PE2023002012A
Other languages
English (en)
Spanish (es)
Inventor
Rubio Paola Yazmin Ollervides
Canudas Jorge Alejandro Gonzales
Leon Sixto Serafin Espinoza
Salazar Claudia Delfina Farfan
Martinez Cecilia Jannette Munoz
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81853431&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20252763(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of PE20252763A1 publication Critical patent/PE20252763A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2023002012A 2020-12-04 2023-07-04 Medicamento de combinacion fija para el control y manejo del dolor neuropatico PE20252763A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050050 WO2022119430A1 (es) 2020-12-04 2020-12-04 Composición farmacéutica sólida recubierta y estable de un analgésico opioide y un antiepiléptico para el dolor

Publications (1)

Publication Number Publication Date
PE20252763A1 true PE20252763A1 (es) 2025-12-22

Family

ID=81853431

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023002012A PE20252763A1 (es) 2020-12-04 2023-07-04 Medicamento de combinacion fija para el control y manejo del dolor neuropatico
PE2023002013A PE20252750A1 (es) 2020-12-04 2023-07-04 Composicion farmaceutica solida recubierta y estable de un analgesico opioide y un antiepileptico para el dolor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2023002013A PE20252750A1 (es) 2020-12-04 2023-07-04 Composicion farmaceutica solida recubierta y estable de un analgesico opioide y un antiepileptico para el dolor

Country Status (10)

Country Link
US (1) US20240000727A1 (enExample)
EP (1) EP4230199A4 (enExample)
JP (1) JP7720911B2 (enExample)
KR (1) KR20230117591A (enExample)
CA (1) CA3199166A1 (enExample)
CO (1) CO2023008896A2 (enExample)
DO (1) DOP2023000095A (enExample)
MX (1) MX2022015331A (enExample)
PE (2) PE20252763A1 (enExample)
WO (1) WO2022119430A1 (enExample)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020187996A1 (en) 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
RU2006118801A (ru) 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
TW200640497A (en) 2005-01-21 2006-12-01 Pharmanova Inc Pharmaceutical formulations and methods of use
JP2007018123A (ja) 2005-07-06 2007-01-25 Kyocera Mita Corp 画像処理装置、及び画像処理システム
MXPA05011735A (es) 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2242737A1 (en) 2007-12-21 2010-10-27 Synthon B.V. Pregabalin salts
TR200909613A1 (tr) 2009-12-22 2011-07-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Pregabalinin farmasötik bileşimleri.
EP2575798B1 (en) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
WO2012048294A2 (en) * 2010-10-07 2012-04-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US20150313892A1 (en) * 2014-02-07 2015-11-05 Trinity Laboratories, Inc. Pharmaceutical compositions for treating pain associated with dysmenorrhea
AU2017300185B2 (en) 2016-07-17 2023-02-02 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
MX2017016720A (es) 2017-12-19 2019-06-20 Monte Verde S A Composición farmacéutica que contiene un analgésico de tipo opioide en combinación con un análogo del ácido g-aminobutírico (gaba).
KR20190075718A (ko) * 2017-12-21 2019-07-01 주식회사 네비팜 용출율이 개선된 트라마돌 또는 이의 약학적으로 허용가능한 염 및 프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 다층 제제
WO2020044070A1 (es) * 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático

Also Published As

Publication number Publication date
US20240000727A1 (en) 2024-01-04
PE20252750A1 (es) 2025-12-05
WO2022119430A1 (es) 2022-06-09
CO2023008896A2 (es) 2023-08-18
JP2024504902A (ja) 2024-02-02
EP4230199A4 (en) 2024-07-31
MX2022015331A (es) 2023-02-01
JP7720911B2 (ja) 2025-08-08
EP4230199A1 (en) 2023-08-23
CA3199166A1 (en) 2022-06-09
DOP2023000095A (es) 2023-06-15
KR20230117591A (ko) 2023-08-08

Similar Documents

Publication Publication Date Title
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2023541432A5 (enExample)
MX2019001103A (es) Sistema de suministro transdermico de donepezilo.
MXPA03010991A (es) Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
CL2022003512A1 (es) Formas farmacéuticas osmóticas que comprenden deutetrabenazina y métodos de uso de las mismas
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
MX2023012741A (es) Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
JP2025507472A5 (enExample)
CR7049A (es) Empleo de flumazenilo en la elaboracion de una medicacion para el tratamiento de la dependencia del alcohol
MX2023003097A (es) Composiciones farmaceuticas que comprenden un oligonucleotido antisentido para administracion oral.
CO2026000726A2 (es) Una forma farmacéutica sólida de dosificación bucodispersable de safinamida
AR127966A1 (es) Formulaciones tópicas de inhibidores de pi3k-delta
CO2025007025A2 (es) Formulaciones orales compactables de ibutamoren
MX2021011795A (es) Composición farmaceutica que comprende esomeprazol 0 sal farmaceuticamente aceptable del mismo y que tiene un perfil de liberación doble.
ECSP003685A (es) Formulaciones orales de liberacion controlada
AR052567A1 (es) Combinacion de bambuterol e inhibidor de integrina
ES2572180T3 (es) Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor